[6-K] Haleon plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc announced the purchase of 1,996,340 ordinary shares under the second tranche of its buyback programme. The trades executed on the London Stock Exchange on 29 September 2025 at an average price of £330.3042 per share. The company intends to hold the purchased shares as treasury shares.

After settlement, registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 42,900,783 are treasury shares, leaving 8,909,452,865 ordinary shares with voting rights. A full breakdown of individual trades is available at the provided RNS link and on the company's investor website.

Positive

• Transparent disclosure of the trade date, number of shares purchased and average price with a link to a full trade breakdown
• Purchased shares to be held as treasury, giving the company flexibility to reissue or cancel shares in the future

Negative

• No information provided on remaining buyback capacity or total programme size, limiting clarity on overall capital allocation
• Announcement omits explicit cash amount spent and does not state whether shares will be cancelled, restricting assessment of net share count impact

Insights

Corporate Governance Expert

TL;DR: A modest-in-scale buyback increases treasury holdings and reduces outstanding voting stock, affecting share count and voting base.

The purchase of 1.996 million shares held in treasury reduces the number of voting shares to 8.909 billion, which is the figure shareholders should use to assess notification thresholds under FCA rules. The disclosure follows Market Abuse Regulation requirements by providing a trade breakdown link. The announcement is procedural and compliant; it does not provide buyback programme size or timing details for further governance implications.

Equity Analyst

TL;DR: Share repurchase completed at ~£330.30 per share; treasury increase is disclosed but impact on capital allocation is not quantified.

The announced average price of £330.3042 for 1,996,340 shares quantifies cash deployment for this tranche (~£659.5 million on a straight multiply basis, calculated from figures in the disclosure). The company states intent to hold as treasury shares, which may support future flexibility for reissuance or cancellation. The release lacks context on remaining repurchase capacity or buyback timetable, limiting assessment of broader capital-return strategy.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐           

EXHIBIT INDEX

Exhibit Number	Description
99.1	30 September 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

30 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,996,340 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	29 September 2025	29 September 2025	29 September 2025
Number of Shares purchased:	1,996,340	-	-
Highest price paid per Share (p):	331.6000	-	-
Lowest price paid per Share (p):	328.7000	-	-
Volume weighted average price paid per Share (p):	330.3042	-	-

The Company intends to hold the purchased shares as treasury shares.

Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 42,900,783 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,909,452,865 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/2957B_1-2025-9-29.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 30, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many shares did Haleon (HLN) buy back on 29 September 2025?

1,996,340 ordinary shares were purchased on 29 September 2025.

At what price did Haleon (HLN) execute the share purchases?

Average price £330.3042 per share (individual trade breakdown available at the RNS link).

Will the repurchased Haleon shares have voting rights?

No; the company intends to hold the purchased shares as treasury shares, so they are not included in the voting total.

What is Haleon's (HLN) number of voting shares after this transaction?

8,909,452,865 ordinary shares with voting rights following settlement.

Where can I find the full breakdown of Haleon's trades?

Full trade breakdown is available at the RNS link provided in the announcement and on www.haleon.com/investors.